Athira Pharma, Inc. — Director's Dealing 2025

Mar 4, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Athira Pharma, Inc. (ATHA)
CIK: 0001620463
Period of Report: 2025-03-03

Reporting Person: Renninger Robert (N/A)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-03-03	Stock Option (Right to Buy)	$0.3762	A	58500	Acquired	2035-03-02	Common Stock (58500)	Direct
2025-03-03	Stock Option (Right to Buy)	$0.3762	A	73350	Acquired	2035-03-02	Common Stock (73350)	Direct
2025-03-03	Restricted Stock Units	$	A	39000	Acquired		Common Stock (39000)	Direct

Footnotes

F1: The shares subject to the option shall be scheduled to vest monthly over a term of 48 months on the monthly anniversaries of the grant date, subject to the optionee continuing to be a Service Provider (as defined in the Issuer's 2020 Equity Incentive Plan) through the applicable vesting dates.

F2: One fourth (1/4th) of shares subject to the option shall be scheduled to vest on the one (1)-year anniversary of the anniversary of the grant date, and one thirty-sixth (1/36th) of the Shares subject to the Option each month thereafter on the same day of the month as the grant date subject to the optionee continuing to be a Service Provider (as defined in the Issuer's 2020 Equity Incentive Plan) through the
applicable vesting dates.

F3: Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of Issuer's common stock.

F4: 100% of the RSUs shall vest on the one (1) year anniversary of the grant date, subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2020 Equity Incentive Plan (the "Plan")) through the vesting date.